Patents by Inventor Berta Moritz

Berta Moritz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5643739
    Abstract: An improved assay for determining sensitivity to activated protein C in test samples has been developed to ensure rapid and accurate evaluations. This assay is based on measuring the conversion, by activated factor VIII within a test sample, of added factor X to an activated form. The activated protein C sensitivity of the test sample is determined by the relative inhibition of factor X conversion as compared to a control. A test sample that has decreased sensitivity to activated protein C will show relatively low inhibition, and vice versa.
    Type: Grant
    Filed: May 1, 1995
    Date of Patent: July 1, 1997
    Assignee: Immuno AG
    Inventors: Katalin Varadi, Hans Peter Schwarz, Hartmut Lang, Berta Moritz
  • Patent number: 5529905
    Abstract: There is disclosed the use of prothrombin fragments, preferably of human prothrombin fragments, having a thrombin-like activity, in particular of meizothrombin, meizo thrombin (desF1), or mixtures thereof, for diagnostic purposes for assaying thrombin substrates as well as a reagent containing these prothrombin fragments.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: June 25, 1996
    Assignee: Immuno Aktiengesellschaft
    Inventors: Hartmut Lang, Berta Moritz
  • Patent number: 5506112
    Abstract: To determine the factor VIII activity of a sample, the latter is reacted with a reagent containing thrombin, factor IXa.beta., phospholipids and calcium ions so as to form a factor VIIIa-factor IXa-phospholipid-calicum ion-containing complex. This complex is reacted with factor X so as to obtain activated factor X. The obtained factor Xa is reacted with chromogenic substrate so as to form a substance to be determined spectrophotometrically. Complex formation and activation of factor X are effected in one stage: The sample is mixed with a mixture of human thrombin, phospholipids, calcium ions, human factor IXa.beta., human factor X and, if desired, human factor XIa and human factor XIIa, as a complex-forming reagent.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: April 9, 1996
    Assignee: Immuno Aktiengesellschaft
    Inventors: Hartmut Lang, Berta Moritz, Manfred Oberreither, Olga Lukas